Latest Insmed News & Updates

See the latest news and media coverage for Insmed. We track all announcements, press releases, and industry mentions in real time, all in one place.

Insmed

Biopharmaceutical company developing therapies for serious diseases

insmed.com

Headquarters: Bridgewater Township, United States
Company type: Public company
Number of employees: 1,800–5,000
Industry: Pharmaceuticals

Last updated Yesterday

Latest news about Insmed

In short: Insmed launched BRINSUPRI in Japan, raised 2026 guidance after Q2 revenue growth, and advanced TPIP and ARIKAYCE.

Company announcements

October 29 Insmed

Insmed reports Q3 2026 revenues of $524.4 million and raises annual guidance

BRINSUPRI and ARIKAYCE drive growth as Insmed launches in Japan, updates pipelines, appoints new board members.

August 24 Insmed

Insmed secures Japanese approval for BRINSUPRI lung therapy

The once-daily oral medication targets non-cystic fibrosis bronchiectasis, marking the first MHLW-approved treatment for this progressive condition in adults and pediatric patients aged 12 and older.

August 6 Insmed

Insmed announces Q2 2026 earnings

The company presents key highlights from the quarter, with the full report available.

August 6 Insmed

Insmed reports Q2 2026 financial results and raises revenue guidance

Total revenues reached $425.5 million; BRINSUPRI brought in $309.2 million. Insmed raised BRINSUPRI's 2026 guidance to $1.25-$1.40 billion and peak revenue estimates to over $14 billion.

Media coverage

Yesterday Yahoo Finance

Insmed (INSM) Begins BRINSUPRI Sales In Japan

Insmed (NasdaqGS: INSM) reported the commercial launch of BRINSUPRI tablets in Japan for non cystic fibrosis bronchiectasis.

October 29 MarketScreener

Insmed Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026

Insmed Incorporated reported earnings results for the third quarter and nine months ended September 30, 2026. For the third quarter, the company reported net loss...

October 29 新浪财经

Insmed rose 2.13%, with a trading volume of $449 million

On October 29, Insmed (INSM) closed up 2.13% at $96.98, with a trading volume of $449 million and a market capitalization of $21.179 billion. The company's latest financial report showed quarterly revenue of $425 million, a year-on-year increase of 296.11%; net loss of $13.242 million, compared to a net loss of $322 million in the same period last year. Company Profile: The company is committed to advancing a series of approved drugs and investigational drugs in mid-to-late stage research and development. The company's advanced projects focus on respiratory and inflammatory diseases, including one approved in the United States, Europe...

October 28 RTTNews

Insmed Raises FY26 Revenue Outlook For BRINSUPRI And ARIKAYCE, Stock Up In Pre-Market

The company raised its full-year 2026 revenue guidance for BRINSUPRI to a range of $1.35 billion to $1.4 billion from the previous guidance of $1.25...

Never miss news about Insmed

Track Insmed and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Insmed competitors & trending companies

Browse news for competitors to Insmed and other trending companies.